Home Nucleus Pharmaceuticals U.S. Cancer Immunotherapy Market to 2032

U.S. Cancer Immunotherapy Market to 2032

Overview

The U.S. Cancer Immunotherapy Market is expected to reach a 136.01 USD Billion by 2032 and is projected to grow at a CAGR of 17.95% from 2025 to 2032.

Revenue, 2024 (USD Billion)
49.20
Forecast, 2032 (USD Billion)
136.01
CAGR, 2024 - 2032
17.95%
Report Coverage
U.S.

U.S. Cancer Immunotherapy Market 2018-2032 USD Billion

U.S. Cancer Immunotherapy Market, Key Findings (2025-2032)

Market Growth and Projections:

  • Market Size (2024): 49.20 USD Billion
  • Projected Market Size (2032): 136.01 USD Billion
  • CAGR (2025-2032): 17.95%

Key Findings of U.S. Cancer Immunotherapy Market

  • The U.S. Cancer Immunotherapy Market was valued at 49.20 USD Billion in 2024.
  • The U.S. Cancer Immunotherapy Market is likely to grow at a CAGR of 17.95% during the forecast period of 2024 to 2032.
  • In 2024, the Largest segment Intravenous (IV) in Form Segment accounted for the largest share of the market with a revenue of 44.18 USD Billion
  • The fastest growing segment Lung Cancer in Application Segment grew Fastest with a CAGR of 25.19% during the forecast period from 2024 to 2032.

U.S. Cancer Immunotherapy Market Scope

U.S. Cancer Immunotherapy Market Segmentation & Scope
Product
  • Monoclonal Antibodies
  • Vaccines
  • Cell Therapies
  • Checkpoint Inhibitors
  • Oncolytic Virus
  • Immunomodulators
Application
  • Lung Cancer
  • Breast Cancer
  • Stomach Cancer
  • Colorectal Cancer
  • Head & Neck Cancer
  • Others
  • Melanoma
  • Multiple Myeloma
  • Prostate Cancer
  • Ovarian Cancer
  • Cervical Cancer
End User
  • Hospitals
  • Oncology Clinics
  • Homecare
  • Others
Form
  • Intravenous (IV)
  • Intramuscular
  • Oral
Distribution Channel
  • Direct Tenders
  • Retail Sales
  • Pharmacies

U.S. Cancer Immunotherapy Market Data Coverage Insights

Study Period 2024-2032
Base Year 2021
Unit Revenue in USD Billion
Market Value in 2024 49.20 USD Billion
Market Value in 2032 136.01 USD Billion
CAGR (2025-2032) 17.95%
Historic Data 2016-2023
Market Segments Covered Product,Application,End User,Form,Distribution Channel

Regional Insights:

  • Leading Market (2024-2032): U.S., leading in terms of revenue 49.20 USD Billion in 2024
    • Key Country: U.S., leading in terms of revenue with value of 49,196.57 USD Million in 2024.

Segments and Scope

  • U.S. Cancer Immunotherapy Market to 2032, By Product
    • Checkpoint Inhibitors is the largest segment in U.S. Cancer Immunotherapy Market to 2032 with a revenue of 31.86 USD Billion in the year 2024.
    • Cell Therapies is the Fastest growing segment in U.S. Cancer Immunotherapy Market to 2032 with a Growth rate of 18.10 % in forecast period 2025-2032.
  • U.S. Cancer Immunotherapy Market to 2032, By Application
    • Lung Cancer is the largest segment in U.S. Cancer Immunotherapy Market to 2032 with a revenue of 8.03 USD Billion in the year 2024.
    • Lung Cancer is the Fastest growing segment in U.S. Cancer Immunotherapy Market to 2032 with a Growth rate of 25.19 % in forecast period 2025-2032.
  • U.S. Cancer Immunotherapy Market to 2032, By End User
    • Hospitals is the largest segment in U.S. Cancer Immunotherapy Market to 2032 with a revenue of 32.56 USD Billion in the year 2024.
    • Hospitals is the Fastest growing segment in U.S. Cancer Immunotherapy Market to 2032 with a Growth rate of 18.16 % in forecast period 2025-2032.
  • U.S. Cancer Immunotherapy Market to 2032, By Form
    • Intravenous (IV) is the largest segment in U.S. Cancer Immunotherapy Market to 2032 with a revenue of 44.18 USD Billion in the year 2024.
    • Intravenous (IV) is the Fastest growing segment in U.S. Cancer Immunotherapy Market to 2032 with a Growth rate of 18.06 % in forecast period 2025-2032.
  • U.S. Cancer Immunotherapy Market to 2032, By Distribution Channel
    • Direct Tenders is the largest segment in U.S. Cancer Immunotherapy Market to 2032 with a revenue of 31.49 USD Billion in the year 2024.
    • Direct Tenders is the Fastest growing segment in U.S. Cancer Immunotherapy Market to 2032 with a Growth rate of 18.64 % in forecast period 2025-2032.

U.S. Cancer Immunotherapy Market Company Share Analysis

 
Company Name Company Share Analysis
Merck & Co., Inc.
Janssen Pharmaceuticals, Inc.
Bristol-Myers Squibb Company
AstraZeneca
Gilead Sciences, Inc.
U.S. Cancer Immunotherapy Market Company Share Analysis

U.S. Cancer Immunotherapy Market Geographical Sales Distribution, 2018-2032 USD Billion

U.S. Cancer Immunotherapy Market Geographical Sales Distribution, 2018-2032 USD Billion

U.S. Cancer Immunotherapy Market Company Profiling

U.S. Cancer Immunotherapy Market Company Profiling

Industry Related Reports

South America Cold Sore Treatment Market
Middle East & Africa Cold Sore Treatment Market
North America Cold Sore Treatment Market
Europe Cold Sore Treatment Market
Asia-Pacific Cold Sore Treatment Market
Argentina Cold Sore Treatment Market
Australia Cold Sore Treatment Market
Austria Cold Sore Treatment Market
Belgium Cold Sore Treatment Market
Brazil Cold Sore Treatment Market
Frequently Asked Questions
The U.S. Cancer Immunotherapy Market is segmented based on Segmentation Product,Application,End User,Form,Distribution Channel.
U.S. Cancer Immunotherapy Market was valued at USD 49.20(Revenue in USD Billion) in 2021.
U.S. Cancer Immunotherapy Market is projected to grow at a CAGR of 17.95% during the forecast period of 2024 to 2032.
The Intravenous (IV) segment is expected to dominate the U.S. Cancer Immunotherapy Market, holding a largest market share of 44.18 USD Billion in 2024

U.S. Cancer Immunotherapy Market Scope

U.S. Cancer Immunotherapy Market Segmentation & Scope
Product
  • Monoclonal Antibodies
  • Vaccines
  • Cell Therapies
  • Checkpoint Inhibitors
  • Oncolytic Virus
  • Immunomodulators
Application
  • Lung Cancer
  • Breast Cancer
  • Stomach Cancer
  • Colorectal Cancer
  • Head & Neck Cancer
  • Others
  • Melanoma
  • Multiple Myeloma
  • Prostate Cancer
  • Ovarian Cancer
  • Cervical Cancer
End User
  • Hospitals
  • Oncology Clinics
  • Homecare
  • Others
Form
  • Intravenous (IV)
  • Intramuscular
  • Oral
Distribution Channel
  • Direct Tenders
  • Retail Sales
  • Pharmacies
Frequently Asked Questions
The U.S. Cancer Immunotherapy Market is segmented based on Segmentation Product,Application,End User,Form,Distribution Channel.
U.S. Cancer Immunotherapy Market was valued at USD 49.20(Revenue in USD Billion) in 2021.
U.S. Cancer Immunotherapy Market is projected to grow at a CAGR of 17.95% during the forecast period of 2024 to 2032.
The estimated market value of the U.S. Cancer Immunotherapy Market for final year is USD 136.01 (USD Billion).

U.S. Cancer Immunotherapy Market Company Profiling

U.S. Cancer Immunotherapy Market Company Profiling
Frequently Asked Questions
The U.S. Cancer Immunotherapy Market is segmented based on Segmentation Product,Application,End User,Form,Distribution Channel.
U.S. Cancer Immunotherapy Market was valued at USD 49.20(Revenue in USD Billion) in 2021.
U.S. Cancer Immunotherapy Market is projected to grow at a CAGR of 17.95% during the forecast period of 2024 to 2032.
The estimated market value of the U.S. Cancer Immunotherapy Market for final year is USD 136.01 (USD Billion).

Related Markets

HAVE A QUESTION?

Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.

BROWSE RELATED PAGES